Access and Barriers to Genomic Classifiers for Breast Cancer and Prostate Cancer in India

Overview

Journal Int J Cancer

Specialty Oncology

Date 2023 Nov 14

PMID 37962056

Authors

Sruthi Ranganathan

Edward Christopher Dee

Neha Debnath

Tej A Patel

Bhav Jain

Vedang Murthy

Affiliations

Soon will be listed here.

Abstract

The incidence of cancer in general, including breast and prostate cancer specifically, is increasing in India. Breast and prostate cancers have genomic classifiers developed to guide therapy decisions. However, these genomic classifiers are often inaccessible in India due to high cost. These classifiers may also be less suitable to the Indian population, as data primarily from patients in wealthy Western countries were used in developing these genomic classifiers. In addition to the limitations in using these existing genomic classifiers, developing and validating new genomic classifiers for breast and prostate cancer in India is challenging due to the heterogeneity in the Indian population. However, there are steps that can be taken to address the various barriers that currently exist for accurate, accessible genomic classifiers for cancer in India.

References

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Reich D, Thangaraj K, Patterson N, Price A, Singh L . Reconstructing Indian population history. Nature. 2009; 461(7263):489-94. PMC: 2842210. DOI: 10.1038/nature08365. View

Spratt D, Dai D, Den R, Troncoso P, Yousefi K, Ross A . Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2017; 74(1):107-114. PMC: 6582359. DOI: 10.1016/j.eururo.2017.11.024. View

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28(11):1829-34. DOI: 10.1200/JCO.2009.24.4798. View

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379(2):111-121. PMC: 6172658. DOI: 10.1056/NEJMoa1804710. View

Chaubey G, Metspalu M, Kivisild T, Villems R . Peopling of South Asia: investigating the caste-tribe continuum in India. Bioessays. 2006; 29(1):91-100. DOI: 10.1002/bies.20525. View

Libbrecht M, Noble W . Machine learning applications in genetics and genomics. Nat Rev Genet. 2015; 16(6):321-32. PMC: 5204302. DOI: 10.1038/nrg3920. View

Lobo J, Trifiletti D, Sturz V, Dicker A, Buerki C, Davicioni E . Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clin Genitourin Cancer. 2017; 15(3):e299-e309. DOI: 10.1016/j.clgc.2016.08.012. View

Xu C, Jackson S . Machine learning and complex biological data. Genome Biol. 2019; 20(1):76. PMC: 6469083. DOI: 10.1186/s13059-019-1689-0. View

10.

Bamshad M, Kivisild T, Watkins W, Dixon M, Ricker C, Rao B . Genetic evidence on the origins of Indian caste populations. Genome Res. 2001; 11(6):994-1004. PMC: 311057. DOI: 10.1101/gr.gr-1733rr. View

11.

Zeigler-Johnson C, Rennert H, Mittal R, Jalloh M, Sachdeva R, Malkowicz S . Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol. 2008; 15(3):4056-64. PMC: 3072889. View

12.

Ebell M . Prolaris Test for Prostate Cancer Risk Assessment. Am Fam Physician. 2019; 100(5):311-312. View

13.

Cuzick J, Stone S, Fisher G, Yang Z, North B, Berney D . Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015; 113(3):382-9. PMC: 4522632. DOI: 10.1038/bjc.2015.223. View

14.

Freedland S, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J . Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86(5):848-53. PMC: 3710548. DOI: 10.1016/j.ijrobp.2013.04.043. View

15.

Batra A, Patel A, Gupta V, Mehta P, Tvsvgk T, Biswas B . Oncotype DX: Where Does It Stand in India?. J Glob Oncol. 2019; 5:1-2. PMC: 6690658. DOI: 10.1200/JGO.19.00151. View

16.

Dalela D, Loppenberg B, Sood A, Sammon J, Abdollah F . Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives. Rev Urol. 2016; 18(1):1-9. PMC: 4859922. View

17.

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

18.

Papiha S, Mukherjee B, Chahal M, Malhotra K, Roberts D . Genetic heterogeneity and population structure in north-west India. Ann Hum Biol. 1982; 9(3):235-51. DOI: 10.1080/03014468200005731. View

19.

Ozmen V, Cakar B, Gokmen E, Ozdogan M, Guler N, Uras C . Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study. Eur J Breast Health. 2019; 15(3):183-190. PMC: 6619785. DOI: 10.5152/ejbh.2019.4761. View

20.

Xing J, Watkins W, Hu Y, Huff C, Sabo A, Muzny D . Genetic diversity in India and the inference of Eurasian population expansion. Genome Biol. 2010; 11(11):R113. PMC: 3156952. DOI: 10.1186/gb-2010-11-11-r113. View